Posttreatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer

Neoplasma

Volumn 52, Issue 5, 2005, Pages 393-397

  Feltl, D ^a   Zavadova E ^b   Pala M ^c   Hozak P ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^d INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Head and neck cancer; Late morbidity; Radiotherapy; TGF beta1

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MORBIDITY; PREDICTION; TREATMENT OUTCOME; BLOOD; DRUG EFFECT; HEAD AND NECK TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RADIATION EXPOSURE; RADIOTHERAPY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 26044478913     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. ADELSTEIN DJ, LIY, ADAMS GL, WAGNER H, KISH JA et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21(1): 92-98.
2. ALLAL AS, TAUSSKY D, MACH N, BECKER M, BIERI S et al. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Int J Radiat Oncol Biol Phys 2004; 58(5): 1431-1436.
3. ANSCHER MS, KONG FM, MARKS LB, BENTEL GC, JIRTLE RL. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997; 37(2): 253-258.
4. ANSCHER MS, MARKS LB, SHAFMAN TD, CLOUGH R, JUANY H et al. Risk of long-term complications after TGF-β1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56(4): 988-995.
5. BARTHELEMY-BRICHANT N, DAVID JL, BOSQUEE L, BURY T, SEIDEL L et al. Increased TGF β1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest 2002; 32(3): 193-198.
6. BERNIER J, BENTZEN SM. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003; 39(5): 560-571.
7. BIER H. Epidemiology of cancer. Changes in incidence of malignant tumors in the head and neck area. HNO 1994; 42(7): 390-392.
8. BLOBE GC, SCHIEMANN WP, LODISH HF. Mechanisms of disease: role of transforming growth factor β in human disease. N Engl J Med 2000; 342: 1350-1358.
9. DE JAEGER K, SEPPENWOOLDE Y, KAMPINGA HH, BOERSMA LJ, BELDERBOS JS et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58(5): 1378-1387.
10. DENIS F, GARAUD P, BARDET E, ALFONSI M, SIRE C et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22(1): 69-76.
11. DICKSON J, DAVIDSON SE, HUNTER RD, WEST CM. Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000; 48(4): 991-995.
12. HADDAD RI, WIRTH L, POSNER MR. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther 2003; 3(3): 331-338.
13. HORIOT JC, BONTEMPS P, VAN DEN BOGAERT W, LE FUR R, VAN DEN WEIJNGAERT D et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44(2): 111-121.
14. IVANOVIC V, TODOROVIC-RAKOVIC N, DEMAJO M, NESKOVIC-KONSTANTINOVIC Z, SUBOTA V et al. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 2003; 39(4): 454-461.
15. LANGE I, HAMMERER P, KNABBE C, GRAEFEN M, SCHMAHL M et al. Plasma TGF-β1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia. Urologe A 1998; 37(2): 199-202.
16. LI C, WILSON PB, LEVINE E, BARBER J, STEWART AL et al. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer 1999; 84(2): 155-159.
17. LIU P, MENON K, ALVAREZ E, LU K, TEICHER BA. Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol 2000; 16(3): 599-610.
18. MAEHARA Y, KAKEJI Y, KABASHIMA A, EMI Y, WATANABE A et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17(2): 607-614.
19. MILAS L, MASON KA, LIAO Z, ANG KK. Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003; 25(2): 152-167.
20. PROSNITZ RG, ANSCHER MS, HUANG H. Does pre-treatment plasma transforming growth factor beta (TGF-1) level predict outcome in breast cancer patients following radiotherapy? Int J Radiat Oncol Biol Phys 2003; 57 Suppl 2: S202-203.
21. SHARIAT SF, SHALEV M, MENESSES-DIAZ A, KIM IY, KATTAN MW et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001; 19(11): 2856-2864.
22. SINGER AJ, CLARK RAF. Mechanisms of Disease: Cutaneous Wound Healing. N Engl J Med 1999; 341: 738-746.
23. SONG BC, CHUNG YH, KIM JA, CHOI WB, SUH DD et al. Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002; 94(1): 175-180.
24. THERASSE P, ARBUCK SG, EISENHAUER EA, WANDERS J, KAPLAN RS et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
25. TSUSHIMA H, ITO N, TAMURA S, MATSUDA Y, INADA M et al. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 2001; 7(5): 1258-1262.
26. WU HS, LI YF, CHOU CI, YUAN CC, HUNG MW et al. The concentration of serum transforming growth factor beta-1 (TGF-beta1) is decreased in cervical carcinoma patients. Cancer Invest 2002; 20(1): 55-59.
27. WUNDERLICH H, STEINER T, KOSMEHL H, JUNKER U, REINHOLD D et al. Increased transforming growth factor β plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol Int 1998; 60(4): 205-207.
28. ZEISBERG M, KALLURI R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82(3): 17.